MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
By R. Rupaimoole, Frank J. Slack. Nature reviews. Drug discovery, 2017
4,226 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/dfa85a98dc633bbd0efe09c827c09e754f6d1dba
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
Citations in the corpus
- An overview of microRNAs: Biology, functions, therapeutics, and analysis methods (2018, methodology): “Another miRNAs that have been targeted using miRNA mimics in preclinical studies are miR‐200/26a/506/520 and 15/16 cluster (Rupaimoole & Slack, 2017).”
- Non-coding RNAs in disease: from mechanisms to therapeutics (2023, positive): “…recent reviews have extensively discussed a range of approaches to modulate the therapeutic potential of ncRNAs, including the use of small interfering RNAs (siRNAs), ASOs, shRNAs, anti-miRNAs, miRNA mimics, miRNA sponges, therapeutic circRNAs and CRISPR–Cas9-based gene editing 53,105,275–278 .”
- TransmiR v2.0: an updated transcription factor-microRNA regulation database (2018, background): “In recent years, abundant evidence has shown that the deregulation of specific miRNA is associated with various diseases like cancers (2,4), cardiovascular diseases (5,6), and psychiatric disorders (7,8).”
- miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions (2017, positive): “miRTarBase has recently been used to conduct integrative analysis in many high quality miRNA related studies, such as clarifying the super-enhancer-mediated RNA processing mechanism (41), informing the miRNA dysregulation in autism spectrum disorder (ASD) and neurological disease (42), supporting th”
- HMDD v3.0: a database for experimentally supported human microRNA–disease associations (2018, background): “For example, miRNAs can both promote and suppress cancers occurrence and progression, and they can serve as diagnosis and prognosis biomarkers (8–11) and novel therapeutic targets for the treatment of cancers (12,13).”
- Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics (2017, background): “and the novel treatment strategies such as multitarget drugs (25,26,31), drug combinations (27,28,52), monoclonal antibodies (61) and RNA therapeutics (62) for enhanced therapeutics and for overcoming drug resistances (21,22).”